{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-273373","form_type":"8-K","ticker":"SEPN","cik":"0001984086","company_name":"Septerna, Inc.","filed_at":"2025-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:41.216829+00:00","generated_at":"2026-05-16T22:41:29.167115+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Septerna reports Q3 net income of $8.2M; cash at $561.6M into 2029; SEP-479 candidate selected","bullets":["Q3 2025 net income $8.2M vs net loss $20.5M in Q3 2024; revenue $21.5M from Novo Nordisk collaboration.","Cash and equivalents $561.6M, including $195M upfront from Novo Nordisk and $12.5M from Vertex; runway into 2029.","Selected SEP-479 as oral PTH1R agonist development candidate for hypoparathyroidism; Phase 1 expected H1 2026.","SEP-631 Phase 1 ongoing for mast cell diseases; initial data expected H1 2026.","Appointed Keith Gottesdiener, M.D., to Board as chair of R&D Committee."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-273373","json":"https://secwatch.observer/filing/0001193125-25-273373.json","markdown":"https://secwatch.observer/filing/0001193125-25-273373.md","text":"https://secwatch.observer/filing/0001193125-25-273373.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1984086/000119312525273373/0001193125-25-273373-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1984086/000119312525273373/sepn-20251110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T22:41:29.167115+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}